Fig. 1

Metabolic markers of T1DM in studied groups. The figure depicts levels of fasting C-peptide (a), daily doses of insulin/kg b.w. (DDI/kg) (b), levels of HbA1c (c) and fasting glucose (d) in T1DM children during the follow-up: NO Tregs—untreated control group, single dose—patients treated with a single infusion, and two doses—patients treated with two infusions of Tregs. The following values of HbA1c in NGSP units (%) match the IFCC units (mmol/mol): 3 = 9, 6 = 42, 9 = 75, 12 = 108, and 15 = 140. Data are presented as medians (min.–max.), while open circles represent particular patients. The significant differences in p values are shown in the figure: a comparisons of C-peptide levels in Kruskal–Wallis ANOVA between three groups at the 4th month (*) and 12 month (&) and Mann–Whitney U test comparison between the untreated group and the group treated with two doses of Tregs at the 24th month (#); b comparisons of daily doses of insulin in Kruskal–Wallis ANOVA between three groups at the 4th (*), 12 (&), and 24th month (#); c comparisons of hemoglobin A1c levels in Kruskal–Wallis ANOVA between three groups at day 0 ($) and the 12 month (&); d comparisons of fasting glucose levels in Kruskal–Wallis ANOVA between three groups at the 4th month (*) and 24th month (#)